Related Experiment Video
Updated: May 19, 2026
10:52
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Waldenström macroglobulinemia: my way
1Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA. gertz.morie@mayo.edu
Leukemia & Lymphoma
|August 7, 2012
Summary
Waldenström macroglobulinemia is a rare lymphoma characterized by IgM protein. Current treatments offer a median survival exceeding 10 years, with rituximab-based regimens showing promise.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma.
- Diagnosis requires a serum monoclonal IgM protein.
- Clinical manifestations include anemia, thrombocytopenia, and hyperviscosity symptoms.
Purpose of the Study:
- To provide an overview of Waldenström macroglobulinemia.
- To discuss diagnostic criteria and prognostic factors.
- To review current and emerging treatment strategies.
Main Methods:
- Review of existing literature and clinical guidelines.
- Analysis of prognostic indicators including the International Staging System.
- Summary of therapeutic agents and preferred treatment regimens.
Main Results:
- The International Staging System aids in prognostication.
- Some WM cases present as a smoldering form requiring observation.
- Established treatments and novel agents are available for active disease.
Conclusions:
- Waldenström macroglobulinemia is a manageable hematologic malignancy.
- Prognosis has improved significantly, with median survival over 10 years.
- Personalized treatment approaches are crucial for optimal patient outcomes.
